New therapies for neuromyelitis optica spectrum disorder

alkiviadis.1961 shared this article with you from Inoreader [Rapid Review] New therapies for neuromyelitis optica spectrum disorder Via The Lancet Neurology Neuromyelitis optica spectrum disorder is an autoimmune disease of the CNS that primarily affects the optic nerves and spinal cord. Most patients have serum antibodies targeting the aquaporin-4 water channel expressed on the end-feet of astrocytes. Although the prevalence of neuromyelitis optica spectrum disorder is limited to around 1–2 people per 100 000, severe immune-mediated attacks can quickly lead to blindness and paralysis if undiagnosed and untreated. However, diagnosis is straightforward when the highly specific serum aquaporin-4 antibodies are detected with cell-based assays. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.